Propanc Biopharma (OTCMKTS:PPCB) Stock Price Down 4% – What’s Next?

Propanc Biopharma Inc (OTCMKTS:PPCB) traded down 4% on Wednesday . The stock traded as low as $0.2006 and last traded at $0.2015. 316,130 shares were traded during mid-day trading, a decline of 84% from the average session volume of 1,929,584 shares. The stock had previously closed at $0.21.

Propanc Biopharma Price Performance

The business has a fifty day moving average of $0.37 and a 200-day moving average of $1.43. The firm has a market cap of $3.20 million, a PE ratio of -0.02 and a beta of 3.66. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On Propanc Biopharma

A hedge fund recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC bought a new position in shares of Propanc Biopharma Inc (OTCMKTS:PPCB) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.33% of Propanc Biopharma at the end of the most recent quarter.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.